The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy, but investors are worried whether it will be good enough to retake the lead from rival Eli Lilly ...

A trial participant lost 18% of her weight but reported severe side effects, including nausea, fatigue, and brain fog after each injection ... to Eli Lilly And Co's LLY Zepbound (Mounjaro).

Tirzepetide is sold under the brand name Mounjaro by Eli Lilly which is a prescription medication and it’s a once-weekly injection. When asked at what stage of regulatory approvals Lilly is, Batterham ...

Our guide will compare the benefits ... you may have come across Zepbound and Mounjaro. Though they have different names, they’re essentially the same medication created and produced by the company ...

Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug... By Patrick Wingrove and Bhanvi Satija (Reuters) -U.S. and UK ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...